Investigational drug · Phase 2
B013
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Platinum-resistant Recurrent Ovarian Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: May 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "B013"
First trial start
2024
Jul 11, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "B013", any sponsor or status.
Conditions studied
As listed on its trial records.
- Platinum-resistant Recurrent Ovarian Cancer
Approved drugs for the same conditions: Ovarian cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "B013" as an intervention, largest first.
Shanghai Jiaolian Drug Research and Development Co., LtdIndustry
NCT06434610 · 90 participants (planned) · Start Jul 11, 2024 · Primary completion Dec 31, 2026
Drug: B013; Paclitaxel and 1 more · For: Platinum-resistant Recurrent Ovarian Cancer
Sites: Beijing, China; Bengbu, China; Changsha, China · 17 sites in all
- Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast CancerPivotal-lookingCompleted
Shanghai Jiaolian Drug Research and Development Co., LtdIndustry
NCT05555706 · 62 participants · Start Dec 6, 2022 · Primary completion Sep 30, 2024
Drug: B013+Nab-Paclitaxel · For: Triple Negative Breast Cancer (TNBC)
Sites: Guangzhou, China; Nanning, China; Haikou, China · 13 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Phenotypic Screening and Marker-Assisted Validation of Sources of Aphis craccivora Koch Resistance in Cowpea (Vigna unguiculata L.).
Gaonosi GG, Lekgari L, Mosupiemang M, et al. · Int J Mol Sci 2025
- Surface-antigen expression profiling (SEP) in B-cell chronic lymphocytic leukemia (B-CLL): Identification of markers with prognostic relevance.
Zucchetto A, Sonego P, Degan M, et al. · J Immunol Methods 2005
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.